Hendrik‐Tobias Arkenau

机构：Sarah Cannon Research Institute · ORCID：0000-0002-2015-1549

发表论文 413 篇 · 总被引 7245 次 · h-index 41

代表论文

• PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials (2024 · ESMO Open · 被引 35)
• Clonal driver neoantigen loss under EGFR TKI and immune selection pressures (2025 · Nature · 被引 33)
• Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors (2024 · Journal of Clinical Oncology · 被引 22)
• First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305 (2025 · Advances in Therapy · 被引 8)
• Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors (2024 · Cancer Medicine · 被引 8)
• Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study (2025 · Current Medical Research and Opinion · 被引 5)